CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 190 enrolled
Drug / intervention
GW685698Xdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00766090
NCT00766090Phase 2Completed

A Multi-Centre, Randomized, Double Blind Cross-over Study to Assess the Non-inferiority of GW685698X 200mcg Once Daily and 100mcg Twice Daily in Adult and Adolescent Patients With Asthma

GlaxoSmithKline·interventional·Posted Oct 3, 2008·Updated Dec 8, 2016

In Brief

A Phase 2 clinical trial evaluating GW685698X for Asthma. Completed, enrolled 190 participants across 16 sites.

Detailed Summary

The purpose of this study is to compare once and twice daily GW685698 in asthma

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 3, 2008
Enrollment StartOct 1, 2008
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.7 years ago

Interventions

GW685698Xdrug

Inhaled Corticosteroid